Pacific Edge (PEB) investor relations material

Opening remarks and agenda

• Meeting opened with a welcome from the Chair and CEO, introduction of directors, management, auditors, and legal counsel, and confirmation of quorum for both in-person and online attendees.

• Agenda included financial review, Q&A, presentations, and formal resolutions as outlined in the notice to shareholders.

Financial performance review

• Operating revenue reached $21.8 million, a 6% year-on-year increase, but also reported an 8.6% decrease due to Medicare loss, with a net loss after tax of $29.9 million.

• Laboratory throughput was 28,894 tests, down 11.5% from the prior year, with US commercial test volumes in 2H25 up 2.7% over 1H25.

• Average U.S. sales price increased to $5.94 per test, with improved cash collections and sales productivity.

• Cash and equivalents stood at $22.6 million, reflecting resilience despite Medicare uncertainty.

• Commercial payer mix increased to 47% of U.S. volumes, reflecting a shift away from Medicare.

Board and executive committee updates

• Chair confirmed intention to retire but agreed to remain for stability until a successor is found.

• Board composition and independence reaffirmed, with directors standing for reelection and new committee roles assigned.

• Audit and Risk Committee leadership transitioned from Sarah Park to Tony Barclay.

• CEO and Chairman delivered key addresses, focusing on strategic direction and operational resilience.